132 related articles for article (PubMed ID: 36396515)
1. Cord blood stem cell-generated KIR
Dizaji Asl K; Rafat A; Mazloumi Z; Valipour B; Movassaghpour A; Talebi M; Mahdavi M; Tayefi Nasrabadi H; Nozad Charoudeh H
Hum Immunol; 2023 Feb; 84(2):98-105. PubMed ID: 36396515
[TBL] [Abstract][Full Text] [Related]
2. Umbilical Cord Blood and iPSC-Derived Natural Killer Cells Demonstrate Key Differences in Cytotoxic Activity and KIR Profiles.
Goldenson BH; Zhu H; Wang YM; Heragu N; Bernareggi D; Ruiz-Cisneros A; Bahena A; Ask EH; Hoel HJ; Malmberg KJ; Kaufman DS
Front Immunol; 2020; 11():561553. PubMed ID: 33178188
[TBL] [Abstract][Full Text] [Related]
3. Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
Bernson E; Hallner A; Sander FE; Wilsson O; Werlenius O; Rydström A; Kiffin R; Brune M; Foà R; Aurelius J; Martner A; Hellstrand K; Thorén FB
Leukemia; 2017 Dec; 31(12):2552-2559. PubMed ID: 28529313
[TBL] [Abstract][Full Text] [Related]
4. NK cell development in a human stem cell niche: KIR expression occurs independently of the presence of HLA class I ligands.
Zhao X; Weinhold S; Brands J; Hejazi M; Degistirici Ö; Kögler G; Meisel R; Uhrberg M
Blood Adv; 2018 Oct; 2(19):2452-2461. PubMed ID: 30266820
[TBL] [Abstract][Full Text] [Related]
5. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
[TBL] [Abstract][Full Text] [Related]
6. Certain Killer Immunoglobulin-Like Receptor (KIR)/KIR HLA Class I Ligand Genotypes Influence Natural Killer Antitumor Activity in Myelogenous Leukemia but Not in Acute Lymphoblastic Leukemia: A Case Control Leukemia Association Study.
Varbanova VP; Mihailova S; Naumova E; Mihaylova AP
Turk J Haematol; 2019 Nov; 36(4):238-246. PubMed ID: 31337191
[TBL] [Abstract][Full Text] [Related]
7. Adaptive single-KIR
Haroun-Izquierdo A; Vincenti M; Netskar H; van Ooijen H; Zhang B; Bendzick L; Kanaya M; Momayyezi P; Li S; Wiiger MT; Hoel HJ; Krokeide SZ; Kremer V; Tjonnfjord G; Berggren S; Wikström K; Blomberg P; Alici E; Felices M; Önfelt B; Höglund P; Valamehr B; Ljunggren HG; Björklund A; Hammer Q; Kveberg L; Cichocki F; Miller JS; Malmberg KJ; Sohlberg E
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319065
[TBL] [Abstract][Full Text] [Related]
8. Both mature KIR+ and immature KIR- NK cells control pediatric acute B-cell precursor leukemia in NOD.Cg-Prkdcscid IL2rgtmWjl/Sz mice.
Kübler A; Woiterski J; Witte KE; Bühring HJ; Hartwig UF; Ebinger M; Oevermann L; Mezger M; Herr W; Lang P; Handgretinger R; Münz C; André MC
Blood; 2014 Dec; 124(26):3914-23. PubMed ID: 25359989
[TBL] [Abstract][Full Text] [Related]
9. Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation.
Pende D; Falco M; Vitale M; Cantoni C; Vitale C; Munari E; Bertaina A; Moretta F; Del Zotto G; Pietra G; Mingari MC; Locatelli F; Moretta L
Front Immunol; 2019; 10():1179. PubMed ID: 31231370
[TBL] [Abstract][Full Text] [Related]
10. Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation.
Zhao XY; Yu XX; Xu ZL; Cao XH; Huo MR; Zhao XS; Chang YJ; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
Blood Adv; 2019 Dec; 3(24):4312-4325. PubMed ID: 31869417
[TBL] [Abstract][Full Text] [Related]
11. Role of natural killer cells for immunotherapy in chronic myeloid leukemia (Review).
Lee HR; Baek KH
Oncol Rep; 2019 May; 41(5):2625-2635. PubMed ID: 30896812
[TBL] [Abstract][Full Text] [Related]
12. Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands.
Chan WK; Kung Sutherland M; Li Y; Zalevsky J; Schell S; Leung W
Clin Cancer Res; 2012 Nov; 18(22):6296-305. PubMed ID: 23014531
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade.
Godal R; Bachanova V; Gleason M; McCullar V; Yun GH; Cooley S; Verneris MR; McGlave PB; Miller JS
Biol Blood Marrow Transplant; 2010 May; 16(5):612-21. PubMed ID: 20139023
[TBL] [Abstract][Full Text] [Related]
14. High-Risk Leukemia: Past, Present, and Future Role of NK Cells.
Mavers M; Bertaina A
J Immunol Res; 2018; 2018():1586905. PubMed ID: 29850617
[TBL] [Abstract][Full Text] [Related]
15. HLA and KIR polymorphisms affect NK-cell anti-tumor activity.
Passweg JR; Huard B; Tiercy JM; Roosnek E
Trends Immunol; 2007 Oct; 28(10):437-41. PubMed ID: 17825623
[TBL] [Abstract][Full Text] [Related]
16. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.
Verheyden S; Ferrone S; Mulder A; Claas FH; Schots R; De Moerloose B; Benoit Y; Demanet C
Cancer Immunol Immunother; 2009 Jun; 58(6):855-65. PubMed ID: 18841361
[TBL] [Abstract][Full Text] [Related]
17. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy.
Spanholtz J; Tordoir M; Eissens D; Preijers F; van der Meer A; Joosten I; Schaap N; de Witte TM; Dolstra H
PLoS One; 2010 Feb; 5(2):e9221. PubMed ID: 20169160
[TBL] [Abstract][Full Text] [Related]
18. Production of cytotoxic, KIR-negative NK cells from CD34+ cord blood cells with the use of Notch signaling.
Beck RC
Transfusion; 2011 Nov; 51 Suppl 4():145S-152S. PubMed ID: 22074625
[TBL] [Abstract][Full Text] [Related]
19. KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells.
Ewen EM; Pahl JHW; Miller M; Watzl C; Cerwenka A
Eur J Immunol; 2018 Feb; 48(2):355-365. PubMed ID: 29105756
[TBL] [Abstract][Full Text] [Related]
20. Activating and inhibitory killer immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell transplantation to cure high-risk leukaemias.
Moretta A; Pende D; Locatelli F; Moretta L
Clin Exp Immunol; 2009 Sep; 157(3):325-31. PubMed ID: 19664139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
